Drugs & Pharmacology Clinical Trials 
This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. 
Subscribe to this data using MyMedWorm.
Subscribe to this data using GoogleReader.
Subscribe to this data using Bloglines.
Subscribe to this data using MyYahoo.
Find the best Christmas presents and January Sales in the UK with this simple shopping directory.
This page shows you the most recent publications within this specialty of the MedWorm directory.
ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
- Platform includes over 100 pharmacology studies, 15 clinical
studies and 2,500 patient exposures
- ANX-188 phase 2-ready in multiple indications outside of
sickle cell disease
SAN DIEGO,
Feb. 26, 2013 /PRNewswire/
-- ADVENTRX... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 26, 2013 Category: Pharmaceuticals Source Type: clinical trials
Discovery of New Antivirals That Block the Progression of the Flu Virus
SHERBROOKE,
QC, Feb. 22, 2013 /CNW Telbec/
- Dr. Martin Richter (pharmacology),
investigator with the Centre de recherche clinique
Étienne-Le Bel (CRCELB) at the Centre hospitalier
universitaire de Sherbrooke (CHUS)
and professor in the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 22, 2013 Category: Pharmaceuticals Source Type: clinical trials
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Conditions: Adverse Drug Events; Adverse Drug ReactionsIntervention: Drug: Qingkailing InjectionSponsors: China Academy of Chinese Medical Sciences; China Academy of Chinese Medical SciencesRecruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 7, 2013 Category: Research Source Type: clinical trials
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Conditions: Adverse Drug Events; Adverse Drug ReactionsIntervention: Drug: Qingkailing InjectionSponsors: China Academy of Chinese Medical Sciences; China Academy of Chinese Medical SciencesNot yet recruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 7, 2013 Category: Research Source Type: clinical trials
Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Conditions: Adverse Drug Events; Adverse Drug ReactionsIntervention: Drug: Qingkailing InjectionSponsors: China Academy of Chinese Medical Sciences; China Academy of Chinese Medical SciencesRecruiting - verified January 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 7, 2013 Category: Research Source Type: clinical trials
Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in Patients with Multiply Relapsed or Refractory Aggressive B-cell NHL Treated with PixuvriTM Who Received Prior Doxorubicin Therapy
SEATTLE, Dec. 17, 2012 /PRNewswire/ -- Cell
Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the
publication of results from a preclinical study of
PixuvriTM (pixantrone) in the The Journal of
Pharmacology and Experimental... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 17, 2012 Category: Pharmaceuticals Source Type: clinical trials
Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American College of Neuropsychopharmacology (ACNP) Annual Meeting
NEW YORK--(BUSINESS WIRE)--Dec 3, 2012 - Forest Laboratories,
Inc. (NYSE: FRX) today announced it will be presenting data on
cariprazine at the American College of Neuropsychopharmacology
Annual Meeting scheduled December 2-6, 2012 in Hollywood,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 3, 2012 Category: Pharmaceuticals Source Type: clinical trials
Research Published in European Journal of Pharmacology Shows that Star Scientific's Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimer's Disease and in Blood
GLEN ALLEN, Va., Nov. 27, 2012 /PRNewswire/ -- Star Scientific,
Inc. (NASDAQ: STSI) today announces that new anatabine research has
been accepted by and published online in the European Journal of
Pharmacology. In a series of studies, researchers at... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 27, 2012 Category: Pharmaceuticals Source Type: clinical trials
Beactica Contributes to Detailed Understanding of Innovative Cancer Drug
UPPSALA, Sweden, October 29, 2012 /PRNewswire/ --Beactica, the
Swedish drug discovery company with world-leading expertise in
molecular interactions, today announced its contribution to a key
paper in the Journal of Pharmacology and... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 29, 2012 Category: Pharmaceuticals Source Type: clinical trials
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Conditions: Pharmacology, Clinical; HealthyInterventions: Drug: Pomalidomide; Drug: Ketoconazole; Drug: Fluvoxamine; Drug: CarbamazepineSponsors: Celgene Corporation; Celgene CorporationRecruiting - verified October 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2012 Category: Research Source Type: clinical trials
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Conditions: Pharmacology, Clinical; HealthyInterventions: Drug: Pomalidomide; Drug: Ketoconazole; Drug: Fluvoxamine; Drug: CarbamazepineSponsors: Celgene Corporation; Celgene CorporationCompleted - verified November 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2012 Category: Research Source Type: clinical trials
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Conditions: Pharmacology, Clinical; HealthyInterventions: Drug: Pomalidomide; Drug: Ketoconazole; Drug: Fluvoxamine; Drug: CarbamazepineSponsors: Celgene Corporation; Celgene CorporationRecruiting - verified October 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2012 Category: Research Source Type: clinical trials
A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Conditions: Pharmacology, Clinical; HealthyInterventions: Drug: Pomalidomide; Drug: Ketoconazole; Drug: Fluvoxamine; Drug: CarbamazepineSponsors: Celgene Corporation; Celgene CorporationCompleted - verified November 2012 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2012 Category: Research Source Type: clinical trials
